Inositol to Reduce Retinopathy of Prematurity

Trial ID or NCT#

NCT01954082

Status

recruiting iconRECRUITING

Purpose

This is a Phase 3, randomized, double-masked, placebo-controlled study designed to determine the effectiveness of myo-Inositol 5% Injection to increase the incidence of survival without severe Retinopathy of Prematurity (ROP) through acute/final ROP determination up to 55 weeks postmenstrual age (PMA) in premature infants <28 0/7 weeks' gestation.

Official Title

INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants

Eligibility Criteria

Ages Eligible for Study: 12 Hours to 72 Hours
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Contact us to find out if this trial is right for you.

Contact

Krisa P. Van Meurs, MD
650-723-5711

SEND MESSAGE

View on ClinicalTrials.gov